Evidence map›Paper›PMID 38911469›Full record

ArticleBlood science (Baltimore, Md.)2024

Ivosidenib in Chinese patients with relapsed or refractory isocitrate dehydrogenase 1 mutated acute myeloid leukemia: a registry study.

Mingyuan Sun, Qingsong Yin, Yang Liang, Chunkang Chang, Jing Zheng, Jian Li, Chunyan Ji, Huiying Qiu, Junmin Li, Yuping Gong and 10 more

Registry-linked trialAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Blood science (Baltimore, Md.), 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT02074839 (A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation), which is not on this map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

NCT02074839 phase1recruitingnot on this map

A Phase I, Multicenter, Open-Label, Dose-Escalation and Expansion, Safety, Pharmacokinetic, Pharmacodynamic, and Clinical Activity Study of Orally Administered AG-120 in Subjects With Advanced Hematologic Malignancies With an IDH1 Mutation

TypeinterventionalSponsorInstitut de Recherches Internationales ServierRan2014 to 2026Enrolled291ConditionsRelapsed or Refractory Acute Myeloid Leukemia (AML), Untreated AML, Other IDH1-mutated Positive Hematologic Malignancies, Myelodysplastic SyndromesArmsAG-120
3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Leukemia epidemiology in China: Burden, trends, and determinants in the 21st century.Chinese journal of cancer research = Chung-kuo yen cheng yen chiu · 2025
    Article
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

20 authors.

Mingyuan SunState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.
Qingsong YinDepartment of Hematology, Henan Cancer Hospital, Zhengzhou, China.
Yang LiangDepartment of Hematologic Oncology, State Key Laboratory of Oncology in South China, Collaborative Innovation Center for Cancer Medicine, Sun Yat-sen University Cancer Center, Guangzhou, China.
Chunkang ChangDepartment of Hematology, Shanghai Sixth People's Hospital Affiliated to Shanghai Jiao Tong University, Shanghai, China.
Jing ZhengDepartment of Hematology, Fujian Medical University Union Hospital, Fuzhou, China.
Jian LiDepartment of Hematology, Peking Union Medical College Hospital, Beijing, China.
Chunyan JiDepartment of Hematology, Qilu Hospital of Shandong University, Jinan, China.
Huiying QiuDepartment of Hematology, The First Affiliated Hospital of Soochow University, Suzhou, China.
Junmin LiDepartment of Hematology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China.
Yuping GongDepartment of Hematology, West China Hospital of Sichuan University, Chengdu, China.
Sheng LuoDepartment of Hematology, The First Affiliated Hospital of Wenzhou Medical University, Wenzhou, China.
Yan ZhangCStone Pharmaceuticals (Suzhou) Co. Ltd., Suzhou, China.
Rumei ChenCStone Pharmaceuticals (Suzhou) Co. Ltd., Suzhou, China.
Zhenwei ShenCStone Pharmaceuticals (Suzhou) Co. Ltd., Suzhou, China.
Zenglian YueCStone Pharmaceuticals (Suzhou) Co. Ltd., Suzhou, China.
Siyuan WangCStone Pharmaceuticals (Suzhou) Co. Ltd., Suzhou, China.
Qingmei ShiCStone Pharmaceuticals (Suzhou) Co. Ltd., Suzhou, China.
Jason YangCStone Pharmaceuticals (Suzhou) Co. Ltd., Suzhou, China.
Jie JinDepartment of Hematology, The First Affiliated Hospital, Zhejiang University, School of Medicine, Hangzhou, China.
Jianxiang WangState Key Laboratory of Experimental Hematology, National Clinical Research Center for Blood Disease, Institute of Hematology and Blood Diseases Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Tianjin, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Ivosidenib, an isocitrate dehydrogenase 1 (

Indexed as

ChinaIDH1 mutationIvosidenibRelapsed or refractory acute myeloid leukemia

Identifiers

PMID38911469
PMCPMC11191922

What Socratic holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.